144P Real-world data of consolidative radiotherapy for extensive stage (ES)-SCLC treated by chemo-immunotherapy (chemo-IO)

Daher, Sameh; Allen, Aaron M.; Rottenberg, Yakir; Nasrallah, Haitam; Yosef, Lilach; Blumenfeld, P.; Wollner, Mira; Appel, Sarit; Nechushtan, Hovav; Moskovitz, Mor; J, Bar; Zer, Alona

doi:10.1016/j.annonc.2022.02.175

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present retrospective study, we included a total of 118 ES-SCLC patients treated with first-line CT-IT, with 45 patients receiving following TRT, which was much more than the 26 patients receiving CT-IT plus TRT in the study of Daher et al The median PFS and OS in the CT-IT + TRT group and CT-IT only group of this study were 8.0 months vs. 5.9 months (HR = 0.64, p = 0.025) and 22.7 months vs. 14.7 months (HR = 0.52, p = 0.015), which were comparable to the results of the study of study of Daher et al [35]. Although the association of TRT and OS failed to reach statistical significance in multivariate analysis, we detected a strong tendency of significant survival benefit in TRT group (HR = 0.564, p = 0.052), which was quite valuable for further investigation in future.…”

Section: Discussionsupporting

confidence: 87%

“…However, several retrospective studies have been conducted and reported most recently. Daher et al conducted a multi-center, academic-initiated retrospective study investigating the efficacy and safety of TRT in ES-SCLC [35]. A total of 126 ES-SCLC patients treated with CT-IT were included with 25 patients in the TRT group and 101 patients in the control group.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer

Xie,

Liu,

et al. 2023

JCM

View full text Add to dashboard Cite

(1) Background: At present, the efficacy and safety of thoracic radiotherapy (TRT) after chemo-immunotherapy (CT-IT) in patients with extensive-stage small-cell lung cancer (ES-SCLC) still remain unclear. The purpose of this study was to evaluate the role of TRT after CT-IT in patients with ES-SCLC. (2) Methods: From January 2020 to October 2021, patients with ES-SCLC treated with first-line anti-PD-L1 antibody plus platinum-etoposide chemotherapy were enrolled retrospectively. The survival data and adverse events data of patients treated with or without TRT after CT-IT were collected for analysis. (3) Results: A total of 118 patients with ES-SCLC treated with first-line CT-IT were retrospectively enrolled, with 45 patients with TRT and 73 patients without TRT after CT-IT. The median PFS and OS in the CT-IT + TRT group and CT-IT only group were 8.0 months versus 5.9 months (HR = 0.64, p = 0.025) and 22.7 months versus 14.7 months (HR = 0.52, p = 0.015), respectively. The median PFS and OS in all 118 patients treated with first-line CT-IT were 7.2 and 19.8 months with an ORR of 72.0%. In multivariate analyses, liver metastasis and response to CT-IT were shown to be independent prognostic factors of PFS (p < 0.05), while liver metastasis and bone metastasis were independent predictive factors of OS (p < 0.05). Although TRT was significantly associated with better PFS and OS in univariate analysis, the association of TRT and OS failed to reach statistical significance (HR = 0.564, p = 0.052) in multivariate analysis. There was no significant difference in adverse events (AEs) between two treatment groups (p = 0.58). (4) Conclusions: ES-SCLC patients treated with TRT after first-line CT-IT had prolonged PFS and OS with an acceptable safety profile. Further prospective randomized studies are necessary to explore the efficacy and safety of this treatment modality for ES-SCLC in future.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer

Xie,

Liu,

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…This suggests that there is an interaction effect between RT and IT in the treatment of ES-SCLC. Daher et al showed that patients who underwent TRT after IT had a signi cantly longer OS (27.7 m vs. 13.2 m, p < 0.007) and PFS (8.5 m vs. 5.6 m, p < 0.003), with an acceptable safety pro le in patients with ES-SCLC [25]. In addition, studies have demonstrated that RT has the potential to increase the expression of tumor antigens on the surface of tumor cells and enhance the binding of antibodies to tumor cells, and IT could enhance the abscopal effect of RT [26,27].…”

Section: Discussionmentioning

confidence: 99%

Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: A real-world study

Sun,

Ji,

Deng

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Patients with extensive-stage small cell lung cancer (ES-SCLC) experience significant therapeutic challenges and limited survival rates. This study aimed to investigate the efficacy of combining immunotherapy (IT) with chemotherapy (CT) for treating ES-SCLC and to explore the synergistic effect between radiotherapy (RT) and IT. Methods This retrospective analysis examined patients with ES-SCLC who received treatment at three centers. Furthermore, propensity score-matched (PSM) analysis was conducted. The Kaplan‒Meier method and Cox proportional hazards regression were used to compare the survival outcomes. Results A total of 257 eligible patients with ES-SCLC were included in the analysis. Among all patients, the median overall survival (mOS) was 18.0m in the chemoimmunotherapy (CT + IT) group and 15.7m in the CT group (p = 0.208). The median real-world progression-free survival (mrwPFS) was 7.7m and 6.8m (p = 0.043) in the CT + IT and CT group, respectively. Moreover, the mOS was 22.0m in the chemoradiotherapy (CT + RT) group and 13.6m in the CT group (p < 0.001). The mrwPFS was 7.4m and 6.0m (p = 0.175) in the CT + RT group and CT group, respectively. The multivariate analyses revealed that sex, liver metastasis and RT were independent prognostic factors for OS (p < 0.05), while liver metastasis and IT were found to be independent predictive factors of rwPFS (p < 0.05). After PSM, the mOS was 23.2m in the CT + IT group and 13.0m in the CT group (p = 0.008). The mrwPFS was 7.3m and 6.2m (p = 0.096) in the CT + IT group and the CT group, respectively. Moreover, the mOS was 21.4m in the CT + RT group and 12.5m in the CT group (p < 0.001). The mrwPFS was 7.3m and 5.2m (p = 0.220) in the CT + RT group and the CT group, respectively. Additionally, our study revealed that in the PD-1 group, RT significantly improved patient survival (36.0m vs. 15.8m, p = 0.041). Conclusion An increasing number of treatment options are being explored for ES-SCLC, and CT is the cornerstone of treatment for this disease. Combining CT with IT and RT has demonstrated remarkable efficacy and excellent safety profiles, and such treatments are worthy of further exploration.

show abstract

Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: A systematic review and meta-analysis

Feng,

Zheng,

Zhang

et al. 2024

Radiotherapy and Oncology

View full text Add to dashboard Cite

144P Real-world data of consolidative radiotherapy for extensive stage (ES)-SCLC treated by chemo-immunotherapy (chemo-IO)

Cited by 4 publications

References 0 publications

Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer

Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer

Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: A real-world study

Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: A systematic review and meta-analysis

Contact Info

Product

Resources

About